tert-Butyl 4-(quinoline-3-carbonyl)piperidine-1-carboxylate

Catalog No. :
ACRRKB865
CAS No. :
669074-89-9
Molecular Formula :
C20H24N2O3
Molecular Weight :
340.42

IUPAC Name:tert-butyl 4-(quinoline-3-carbonyl)piperidine-1-carboxylate

tert-Butyl 4-(quinoline-3-carbonyl)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g97%$406.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(quinoline-3-carbonyl)piperidine-1-carboxylate
IUPAC Nametert-butyl 4-(quinoline-3-carbonyl)piperidine-1-carboxylate
MDL No.MFCD11858565
Molecular FormulaC20H24N2O3
Molecular Weight340.42
SMILESO=C(N1CCC(C(C2=CC3=CC=CC=C3N=C2)=O)CC1)OC(C)(C)C
InChI KeyQQHGUKHUOFGSJW-UHFFFAOYSA-N
Synonym4-(QUINOLINE-3-CARBONYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;tert-Butyl 4-(quinoline-3-carbonyl)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-(3-quinolinylcarbonyl)-, 1,1-dimethylethyl ester;1,1-Dimethylethyl 4-(3-quinolinylcarbonyl)-1-piperidinecarboxylate
CAS No.669074-89-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACRRKB865 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACVLAB945 route compound structure diagram
    ACVLAB9455332-24-1 In Stock
  2. Plus
  3. ACGZNV706 route compound structure diagram
    ACGZNV706139290-70-3 In Stock
  4. Then
  5. ACRRKB865 route product structure diagram
    ACRRKB865669074-89-9
Inquiry

2. ACRRKB865 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRRKB865 route product structure diagram
    ACRRKB865669074-89-9
Inquiry

Comments (0)